MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria® PfSPZ Malaria Vaccine Wins 2014 Vaccine Industry Excellence Award for “Best Prophylactic Vaccine”
Sanaria received the 2014 Vaccine Industry Excellence Award for the “Best Prophylactic Vaccine” at a ceremony held March 25 in Washington DC during the 14th World Vaccine Congress. Vaccines from Sanofi Pasteur, GSK, and Novartis were among the 6 finalists competing with Sanaria.
Minister of Health and Social Welfare Discusses Malaria Vaccine Clinical Trial
In an interview, Equatorial Guinea’s Minister of Health and Social Welfare, Diosdado Vicente Nsue Milang, talks about the government’s partnership with American biotechnology company, Sanaria in conducting a malaria vaccine clinical trial.
Biology grad helping develop breakthrough malaria vaccine
A long sought-after vaccine for malaria, a disease that killed 660,000 people and infected more than 200 million others in 2010, is one huge step closer, thanks to a promising breakthrough developed in part by Peter Billingsley, PhD’85 (Biology).
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2013
600 participated in fifth annual Frontiers in Science and Medicine Day.
Dr. Hoffman vs. the Mosquito
A Rockville scientist has spent 30 years struggling to eradicate malaria, the deadly insect-borne disease that has outwitted generations of medical researchers. Experts have long called his vaccine a fantasy. Now he has one last chance to prove himself.
Malaria specialists meeting in Durban
The Minister of Health, together with the heads of the various departments of the ministry and the institutions collaborating in the fight against the disease in Equatorial Guinea, attended the Sixth Pan-African Malaria Conference, held in Durban (South Africa).
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.